The lipid-lowering effects of lomitapide are unaffected by adjunctive apheresis in patients with homozygous familial hypercholesterolaemia – a post-hoc analysis of a Phase 3, single-arm, open-label trial

OBJECTIVE: Lomitapide (a microsomal triglyceride transfer protein inhibitor) is an adjunctive treatment for homozygous familial hypercholesterolaemia (HoFH), a rare genetic condition characterised by elevated low-density lipoprotein-cholesterol (LDL-C), and premature, severe, accelerated atheroscler...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Atherosclerosis
Autors principals: Stefanutti, C, Blom, DJ, Averna, MR, Meagher, EA, Theron, HdT, Marais, AD, Hegele, RA, Sirtori, CR, Shah, PK, Gaudet, D, Vigna, GB, Sachais, BS, Di Giacomo, S, du Plessis, AME, Bloedon, LT, Balser, J, Rader, DJ, Cuchel, M
Format: Artigo
Idioma:Inglês
Publicat: 2015
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4573555/
https://ncbi.nlm.nih.gov/pubmed/25897792
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.atherosclerosis.2015.03.014
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars